Chemocentryx (CCXI) Return on Equity ROE from the second quarter 2026 to second quarter 2021 and annually, average high and low, overall ranking from Jun 30 2026 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemocentryx Inc.  (NASDAQ: CCXI)

Chemocentryx's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Chemocentryx in the second quarter 2026?
Chemocentryx Inc. achieved a return on average equity (ROE) of 1576.8 % in its second quarter 2026, this is above CCXI's average return on equity of -44.49%.
Chemocentryx Inc. shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $14 million

While the company's net income was fading, Chemocentryx was able to improve its ROE compared to the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 233 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3683 to 3803.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity Change - - - -28.38 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 219 309 -133 -141 -132
Return On Equity (TTM) 1576.8 % 265.13 % -69.4 % -51.27 % -44.25 %
CCXI's Total Ranking # 3803 # 3683 # # #
Equity (TTM) in Millions -153 -14 -14 237 259
Seq. Equity Change - - - -8.58 % -9.58 %
Seq. Net Income Change - - - - -

Back to CCXI Management Effectiveness >> CCXI's 5 Years Annual ROE >> Compare CCXI ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 234
Sector # 552
Overall # 3803

Return On Equity Statistics
High Average Low
39.31 %
-44.49 %
-167.55 %
(Jun 30 2018)   (Dec 31 2018)





CCXI Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Equity in Millions 286 386 66 15 79
Y / Y Equity Change -25.8 % 484.26 % 347.82 % -81.41 % 58.89 %
Net Income in Millions -132 -55 -55 -38 18
Y / Y Net Income Change - - - - -
Return On Equity -46.05 % -14.36 % -84.07 % -257.61 % 22.53 %

Back to CCXI Management Effectiveness >> CCXI's 5 Years Annual ROE >> Compare CCXI ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CCXI's' Return on Equity at Yahoo Finance
CCXI's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CCXI's Competitors
Subscribers only: Roe for Chemocentryx's Suppliers
Subscribers only: Return On Equity for CCXI's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Glucotrack Inc   1,114.03 %
Elutia Inc   940.81 %

Date modified: 2026-09-26T07:44:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.